Media
Press Releases
March 7, 2025
Lupin Launches Rivaroxaban Tablets USP, 2.5mg in the United States
February 27, 2025
Lupin Secures a Place in the Prestigious S&P Global Sustainability Yearbook 2025
February 21, 2025
Lupin Receives EIR from U.S. FDA for its Somerset Manufacturing Facility
February 19, 2025
Lupin Receives “A-” Leadership Rating from CDP in Two Categories – Climate Change and Water Security
February 10, 2025
Lupin and Natco Receive Approval from U.S. FDA for Bosentan Tablets for Oral Suspension
February 3, 2025
Lupin Receives Tentative Approval from U.S. FDA for Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide Tablets
February 1, 2025
Lupin Announces Closure of Inspection by U.S. FDA at its Somerset Facility with No Observations
January 9, 2025
Lupin Receives Tentative Approval from U.S. FDA for Loteprednol Etabonate Ophthalmic Gel
January 8, 2025
Lupin Receives EIR from U.S. FDA for its Pithampur Unit-1 Facility with VAI Classification
Media
Rajalakshmi Azariah
Vice President & Global Head - Corporate Communications
rajalakshmiazariah@lupin.comSmart Guide
Close
CloseSearch Product